CBAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
CymaBay Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 was 12.36%.
As of Dec. 2023, CymaBay Therapeutics has a Sloan Ratio of 12.36%, indicating there is a warning stage of accrual build up.
The historical data trend for CymaBay Therapeutics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Sloan Ratio % | Get a 7-Day Free Trial | 14.32 | -35.25 | -34.18 | 16.96 | 12.36 |
CymaBay Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Sloan Ratio % | Get a 7-Day Free Trial | 16.96 | 0.37 | 13.53 | 2.20 | 12.36 |
For the Biotechnology subindustry, CymaBay Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where CymaBay Therapeutics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
CymaBay Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Sloan Ratio | = | (Net Income (A: Dec. 2023 ) | - | Cash Flow from Operations (A: Dec. 2023 ) |
- | Cash Flow from Investing (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2023 ) | |
= | (-105.37 | - | -72.531 | |
- | -86.569) | / | 434.686 | |
= | 12.36% |
CymaBay Therapeutics's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as
Sloan Ratio | = | (Net Income (TTM) | - | Cash Flow from Operations (TTM)) |
- | Cash Flow from Investing (TTM)) | / | Total Assets (Q: Dec. 2023 ) | |
= | (-105.37 | - | -72.531 | |
- | -86.569) | / | 434.686 | |
= | 12.36% |
CymaBay Therapeutics's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -28.778 (Mar. 2023 ) + -0.808 (Jun. 2023 ) + -33.882 (Sep. 2023 ) + -41.902 (Dec. 2023 ) = $-105.37 Mil. CymaBay Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 6.431 (Mar. 2023 ) + -25.437 (Jun. 2023 ) + -26.145 (Sep. 2023 ) + -27.38 (Dec. 2023 ) = $-72.53 Mil. CymaBay Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -60.642 (Mar. 2023 ) + 0.719 (Jun. 2023 ) + 15.461 (Sep. 2023 ) + -42.107 (Dec. 2023 ) = $-86.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics (NAS:CBAY) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
According to How to Beat the Market with the Sloan Ratio:
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2023, CymaBay Therapeutics has a Sloan Ratio of 12.36%, indicating there is a warning stage of accrual build up.
Thank you for viewing the detailed overview of CymaBay Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Mcwherter | officer: Chief Scientific Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Daniel Menold | officer: Vice President, Finance | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Paul T Quinlan | officer: General Counsel | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Janet Dorling | director | C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Sujal Shah | director, officer: Chief Executive Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Kurt Von Emster | director | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Harish Shantharam | officer: Chief Financial Officer | 7575 GATEWAY BLVD, NEWARK CA 94560 |
Dennis D Kim | officer: Chief Medical Officer | C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803 |
Eric Lefebvre | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Thomas G Wiggans | director | |
Lewis J Stuart | officer: Chief Commercial Officer | 3172 PORTER DRIVE, PALO ALTO CA 94304 |
Venbio Select Advisor Llc | 10 percent owner | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Behzad Aghazadeh | 10 percent owner | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
From GuruFocus
By Marketwired • 08-28-2023
By Marketwired • 09-12-2023
By Marketwired • 09-21-2023
By PRNewswire • 08-10-2023
By Marketwired • 08-10-2023
By Marketwired • 09-15-2023
By GuruFocus Research • 01-12-2024
By Marketwired • 10-31-2023
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 10-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.